Skip to main content
Open Access Publications from the University of California

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.

  • Author(s): Cheedarla, Narayanaiah;
  • Precilla, K Lucia;
  • Babu, Hemalatha;
  • Vijayan, KK Vidya;
  • Ashokkumar, Manickam;
  • Chandrasekaran, Padmapriyadarsini;
  • Kailasam, Nandagopal;
  • Sundaramurthi, Jagadish Chandrabose;
  • Swaminathan, Soumya;
  • Buddolla, Viswanath;
  • Vaniambadi, S Kalyanaraman;
  • Ramanathan, VD;
  • Hanna, Luke Elizabeth
  • et al.

Published Web Location

Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV). In the present study, we screened plasma of 88 HIV-1 infected ART naïve individuals for their neutralization potential using a standard panel of 18 pseudoviruses belonging to different subtypes and different levels of neutralization. We identified 12 samples with good breadth of neutralization (neutralized >90% of the viruses). Four of these samples neutralized even the difficult-to-neutralize tier-3 pseudoviruses with great potency (GMT > 600). Analysis of neutralization specificities indicated that four samples had antibodies with multiple epitope binding specificities, viz. CD4-binding site (CD4BS), glycans in the V1/V2 and V3 regions and membrane proximal external region (MPER). Our findings indicate the strong possibility of identifying highly potent bNAbs with known or novel specificities from HIV-1 subtype C infected individuals from India that can be exploited as therapeutic tools or lead molecules for the identification of potential epitopes for design of a protective HIV-1 vaccine.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View